Amended Statement of Ownership (sc 13g/a)
February 12 2016 - 2:46PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)
(Amendment No. 1)*
NexVet Biopharma PLC |
(Name of Issuer) |
Ordinary Shares |
(Title of Class of Securities) |
December 31, 2015 |
(Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
(Continued on following pages)
Page 1 of 9
Exhibit Index on Page 8
CUSIP # G6503X109 |
Page 2 of 9 |
1 |
NAME OF REPORTING PERSONS Foresite Capital Fund II, L.P. (“FCF II”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
1,074,001 shares (of which 200,000 shares are issuable upon exercise of warrants), except that Foresite Capital Management II, LLC (“FCM II”), the general partner of FCF II, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM II, may be deemed to have sole power to vote these shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
1,074,001 shares (of which 200,000 shares are issuable upon exercise of warrants), except that FCM II, the general partner of FCF II, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM II, may be deemed to have sole power to dispose of these shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
1,074,001 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
9.4% |
12 |
TYPE OF REPORTING PERSON |
PN |
CUSIP # G6503X109 |
Page 3 of 9 |
1 |
NAME OF REPORTING PERSONS Foresite Capital Management II, LLC (“FCM II”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
1,074,001 shares (of which 200,000 shares are issuable upon exercise of warrants), all of which are directly owned by Foresite Capital Fund II, L.P. (“FCF II”). FCM II, the general partner of FCF II, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM II, may be deemed to have sole power to vote these shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
1,074,001 shares (of which 200,000 shares are issuable upon exercise of warrants), all of which are directly owned by FCF II. FCM II, the general partner of FCF II, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM II, may be deemed to have sole power to dispose of these shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
1,074,001 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
9.4% |
12 |
TYPE OF REPORTING PERSON |
OO |
CUSIP # G6503X109 |
Page 4 of 9 |
1 |
NAME OF REPORTING PERSONS James Tananbaum (“Tananbaum”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ¨ (b) x |
3 |
SEC USE ONLY |
4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
5 |
SOLE VOTING POWER
1,074,001 shares (of which 200,000 shares are issuable upon exercise of warrants), all of which are directly owned by Foresite Capital Fund II, L.P. (“FCF II”). Tananbaum is the managing member of Foresite Capital Management II, LLC (“FCM II”), which is the general partner of FCF II. Tananbaum may be deemed to have sole power to vote these shares. |
6 |
SHARED VOTING POWER
See response to row 5. |
7 |
SOLE DISPOSITIVE POWER
1,074,001 shares (of which 200,000 shares are issuable upon exercise of warrants), all of which are directly owned by FCF II. Tananbaum is the managing member of FCM II, which is the general partner of FCF II. Tananbaum may be deemed to have sole power to dispose of these shares. |
8 |
SHARED DISPOSITIVE POWER
See response to row 7. |
9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
1,074,001 |
10 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
¨ |
11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 |
9.4% |
12 |
TYPE OF REPORTING PERSON |
IN |
CUSIP # G6503X109 |
Page 5 of 9 |
ITEM 1(A). |
NAME OF ISSUER |
|
|
|
NexVet Biopharma PLC (the “Issuer”) |
|
|
ITEM 1(B). |
ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES |
|
|
|
National Institute for Bioprocessing Research and Training |
|
Fosters Avenue, Mount Merrion |
|
Blackrock, Co. Dublin |
|
Ireland |
|
|
ITEM 2(A). |
NAME OF PERSONS FILING |
|
|
|
This Schedule is filed by Foresite Capital Fund II, L.P., a Delaware limited partnership, Foresite Capital Management II, LLC, a Delaware limited liability company, and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.” |
|
|
ITEM 2(B). |
ADDRESS OF PRINCIPAL OFFICE |
|
|
|
The address for each of the Reporting Persons is: |
|
|
|
c/o Foresite Capital Management |
|
101 California Street, Suite 4100 |
|
San Francisco, CA 94111 |
|
|
ITEM 2(C). |
CITIZENSHIP |
|
|
|
See Row 4 of cover page for each Reporting Person. |
|
|
ITEM 2(D). |
TITLE OF CLASS OF SECURITIES |
|
|
|
Ordinary Shares |
|
|
ITEM 2(D) |
CUSIP NUMBER |
|
|
|
G6503X109 |
|
|
ITEM 3. |
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: |
|
|
|
Not applicable. |
|
|
ITEM 4. |
OWNERSHIP |
|
|
|
The following information with respect to the ownership of the ordinary shares of the Issuer by the persons filing this Statement is provided as of December 31, 2015: |
|
(a) |
Amount
beneficially owned: |
|
|
|
|
|
See
Row 9 of cover page for each Reporting Person. |
|
|
|
|
(b) |
Percent
of Class: |
|
|
|
|
|
See
Row 11 of cover page for each Reporting Person. |
|
|
|
CUSIP # G6503X109 |
Page 6 of 9 |
|
(c) |
Number
of shares as to which such person has: |
|
(i) |
Sole
power to vote or to direct the vote: |
|
|
|
|
|
See
Row 5 of cover page for each Reporting Person. |
|
|
|
|
(ii) |
Shared
power to vote or to direct the vote: |
|
|
|
|
|
See
Row 6 of cover page for each Reporting Person. |
|
|
|
|
(iii) |
Sole
power to dispose or to direct the disposition of: |
|
|
|
|
|
See
Row 7 of cover page for each Reporting Person. |
|
|
|
|
(iv) |
Shared
power to dispose or to direct the disposition of: |
|
|
|
|
|
See
Row 8 of cover page for each Reporting Person. |
ITEM 5. |
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS |
|
|
|
Not applicable. |
|
|
ITEM 6. |
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. |
|
|
|
Under certain circumstances set forth in the limited partnership agreement of FCF II and the limited liability company agreement of FCM II, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member. |
|
|
ITEM 7. |
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY |
|
|
|
Not applicable. |
|
|
ITEM 8. |
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. |
|
|
|
Not applicable |
|
|
ITEM 9. |
NOTICE OF DISSOLUTION OF GROUP. |
|
|
|
Not applicable |
|
|
ITEM 10. |
CERTIFICATION. |
|
|
|
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
CUSIP # G6503X109 |
Page 7 of 9 |
SIGNATURES
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 12, 2016 |
|
|
|
|
|
|
FORESITE CAPITAL FUND II, L.P. |
|
|
|
|
By: |
FORESITE CAPITAL MANAGEMENT II, LLC |
|
Its: |
General Partner |
|
|
|
|
By: |
/s/ James Tananbaum |
|
Name: |
James Tananbaum |
|
Title: |
Managing Member |
|
|
|
|
FORESITE CAPITAL MANAGEMENT II, LLC |
|
|
|
|
By: |
/s/ James Tananbaum |
|
Name: |
James Tananbaum |
|
Title: |
Managing Member |
|
|
|
|
JAMES TANANBAUM |
|
|
|
|
By: |
/s/ James Tananbaum |
|
Name: |
James Tananbaum |
CUSIP # G6503X109 |
Page 8 of 9 |
EXHIBIT INDEX
|
|
Found on
Sequentially |
Exhibit |
|
Numbered Page |
|
|
|
Exhibit A: Agreement of Joint Filing |
|
9 |
CUSIP # G6503X109 |
Page 9 of 9 |
EXHIBIT A
Agreement of Joint Filing
The Reporting Persons
hereby agree that a single Schedule 13G (or any amendment thereto) relating to the ordinary shares of the Issuer shall be filed
on behalf of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with
the appropriate agencies.
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From May 2024 to Jun 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jun 2023 to Jun 2024